Loading organizations...
Loading organizations...
4BIO Capital: International venture capital firm investing in early-stage life sciences companies, focused on advanced therapies: cell, gene, and RNA.
4BIO Capital is a London-based international venture capital firm that invests exclusively in early-stage life sciences companies developing advanced therapies, including cell and gene treatments, RNA-based medicines, and radiopharmaceuticals. The firm manages multiple venture funds, including 4BIO Ventures II and III, with an estimated assets under management exceeding $300 million while backing a portfolio of over 20 active biotechnology startups. Its investment strategy targets eight to twelve early-stage companies per fund, recently participating in a $100 million Series A funding round for Ray Therapeutics and co-leading a $75.5 million Series A for Actithera. The firm's portfolio includes notable biotech developers such as Trogenix and Orchard Therapeutics, the latter of which was acquired by Kyowa Kirin for up to $477.6 million. 4BIO Capital was founded in 2014 by managing partners Dmitry Kuzmin and Andrew Kozlov.
Key people at 4BIO Capital.
Key people at 4BIO Capital.
4BIO Capital is a London-based venture capital firm specializing exclusively in advanced therapies within the life sciences sector. Their mission is to invest in and support early-stage companies developing transformative treatments—such as gene therapy, cell therapy, RNA-based therapy, targeted therapies, and microbiome-based treatments—that address significant unmet medical and social needs. They focus on curative approaches rather than symptom management, aiming to ensure broad patient access to potentially life-changing therapies. Their investment philosophy emphasizes capital efficiency, milestone-driven development, and active portfolio involvement, primarily targeting early-stage biotech startups across the UK, Europe, and the US[1][2][3].
Founded in 2014, 4BIO Capital was established by a team combining deep scientific expertise and investment experience, including partners like Owen Smith, who brings a unique blend of scientific training and financial acumen. The firm has evolved to emphasize company creation, Series A seeding, and sustained support through multiple funding rounds. Their team has published extensively in top scientific journals, reflecting their strong scientific foundation and network within the advanced therapy sector. This expertise enables them to identify and back the most promising opportunities in the field[1][2][3].
4BIO Capital rides the wave of advanced therapies revolutionizing medicine, where gene and cell therapies are shifting paradigms from chronic disease management to potential cures. The timing is critical as scientific breakthroughs, regulatory support, and increasing capital availability converge to accelerate innovation. By focusing on early-stage companies in this niche, 4BIO helps bridge the gap between cutting-edge science and commercial viability, influencing the biotech ecosystem by fostering high-impact startups that address unmet medical needs globally[1][2][3].
Looking ahead, 4BIO Capital is poised to deepen its influence by continuing to back pioneering therapies that could redefine treatment landscapes. Trends such as personalized medicine, RNA therapeutics, and microbiome modulation will likely shape their investment focus. Their model of combining scientific rigor with financial discipline positions them well to capitalize on emerging opportunities and drive the translation of advanced therapies from lab to patient. This sustained commitment could enhance their role as a key enabler in the life sciences venture capital space, ultimately expanding patient access to transformative treatments[2][3].
